Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17359417 | 0.87 | GAA (0.47) | EPHX2GAAHRH3HPGDALDH1A1 | |
| SCHEMBL17357006 | 0.86 | GAA (0.48) | EPHX2GAAHRH3HPGDALDH1A1 | |
| SCHEMBL14703361 | 0.86 | HRH3 (0.47) | EPHX2GAAHRH3HTR2CBCHE | |
| SCHEMBL14703144 | 0.86 | HRH3 (0.45) | EPHX2HRH3HTR2CBCHEACHE | |
| SCHEMBL14703251 | 0.85 | EPHX2 (0.47) | EPHX2HRH3HTR2CBCHEACHE | |
| SCHEMBL17357002 | 0.84 | EPHX2 (0.69) | EPHX2GAAALDH1A1SMN1; SMN2SCN9A | |
| SCHEMBL17356987 | 0.83 | DPP7 (0.53) | GAAHRH3HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL14703473 | 0.81 | ALDH1A1 (0.51) | EPHX2HRH3HTR2CALDH1A1SMN1; SMN2 | |
| SCHEMBL17356945 | 0.79 | EPHX2 (0.43) | EPHX2HRH3HTR2CBCHEACHE | |
| SCHEMBL17356986 | 0.79 | GAA (0.47) | GAAHRH3ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10252996-B2 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | IMMUNOMET THERAPEUTICS INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180105494-A1 | N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANALL BIOPHARMA CO., LTD. (KP) | 2018-04-19 | — | — | US | disclosed |
| US-20180105494-A1 | N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANALL BIOPHARMA CO., LTD. (KP) | 2018-04-19 | — | — | US | disclosed |
| US-9884821-B2 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | IMMUNOMET THERAPEUTICS INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884821-B2 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | IMMUNOMET THERAPEUTICS INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150368198-A1 | N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | IMMUNOMET THERAPEUTICS INC. | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368198-A1 | N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | PRKG1, PRKAG1, PRKG2 | EPHX2 4222/4885GAA 2614/4885HRH3 3956/4885 |
| US-10252996-B2 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | PRKG1, PRKAG1, PRKG2 | EPHX2 4222/4885GAA 2614/4885HRH3 3956/4885 |
| US-20180105494-A1 | N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | PRKG1, PRKAG1, PRKG2 | EPHX2 4222/4885GAA 2614/4885HRH3 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.